These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

530 related articles for article (PubMed ID: 23039393)

  • 21. Epigenetic Drugs for Mood Disorders.
    Peedicayil J; Kumar A
    Prog Mol Biol Transl Sci; 2018; 157():151-174. PubMed ID: 29933949
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The Compensatory Immune-Regulatory Reflex System (CIRS) in Depression and Bipolar Disorder.
    Maes M; Carvalho AF
    Mol Neurobiol; 2018 Dec; 55(12):8885-8903. PubMed ID: 29611101
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Glycogen synthase kinase-3: a putative molecular target for lithium mimetic drugs.
    Gould TD; Manji HK
    Neuropsychopharmacology; 2005 Jul; 30(7):1223-37. PubMed ID: 15827567
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Treatment-resistant mood disorders].
    Machado-Vieira R; Soares JC
    Braz J Psychiatry; 2007 Oct; 29 Suppl 2():S48-54. PubMed ID: 17713691
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Meta-analysis and review of dopamine agonists in acute episodes of mood disorder: Efficacy and safety.
    Romeo B; Blecha L; Locatelli K; Benyamina A; Martelli C
    J Psychopharmacol; 2018 Apr; 32(4):385-396. PubMed ID: 29543103
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pathologic role of nitrergic neurotransmission in mood disorders.
    Ghasemi M; Claunch J; Niu K
    Prog Neurobiol; 2019 Feb; 173():54-87. PubMed ID: 29890213
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Neuroimmune-endocrine crosstalk in schizophrenia and mood disorders.
    Müller N; Schwarz MJ
    Expert Rev Neurother; 2006 Jul; 6(7):1017-38. PubMed ID: 16831116
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Association of Protein Kinase B (AKT) DNA Hypermethylation with Maintenance Atypical Antipsychotic Treatment in Patients with Bipolar Disorder.
    Burghardt KJ; Seyoum B; Dass SE; Sanders E; Mallisho A; Yi Z
    Pharmacotherapy; 2018 Apr; 38(4):428-435. PubMed ID: 29484683
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Atypical antipsychotics in the treatment of affective symptoms: a review.
    Masan PS
    Ann Clin Psychiatry; 2004; 16(1):3-13. PubMed ID: 15147108
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Healthcare costs associated with treatment of bipolar disorder using a mood stabilizer plus adjunctive aripiprazole, quetiapine, risperidone, olanzapine or ziprasidone.
    Jing Y; Kim E; You M; Pikalov A; Tran QV
    J Med Econ; 2009 Jun; 12(2):104-13. PubMed ID: 19527195
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Anti-inflammatory effects of resveratrol and its potential use in therapy of immune-mediated diseases.
    Švajger U; Jeras M
    Int Rev Immunol; 2012 Jun; 31(3):202-22. PubMed ID: 22587021
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Polyunsaturated fatty acids and recurrent mood disorders: Phenomenology, mechanisms, and clinical application.
    Messamore E; Almeida DM; Jandacek RJ; McNamara RK
    Prog Lipid Res; 2017 Apr; 66():1-13. PubMed ID: 28069365
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical psychopharmacology of pediatric mood stabilizer and antipsychotic treatment, part 1: challenges and developments.
    Correll CU
    J Clin Psychiatry; 2007 Aug; 68(8):1301-2. PubMed ID: 17854257
    [No Abstract]   [Full Text] [Related]  

  • 34. Correlation between brain damage, associated biomarkers, and medication in psychiatric inpatients: A cross-sectional study.
    Yoshida M; Kanzaki T; Mizoi M; Nakamura M; Uemura T; Mimori S; Uju Y; Sekine K; Ishii Y; Yoshimi T; Yasui R; Yasukawa A; Sato M; Okamoto S; Hisaoka T; Miura M; Kusanishi S; Murakami K; Nakano C; Mizuta Y; Mishima S; Hayakawa T; Tsukada K; Kashiwagi K; Igarashi K
    Clin Chim Acta; 2017 Jan; 464():50-56. PubMed ID: 27816667
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Role of neuro-immunological factors in the pathophysiology of mood disorders.
    Bhattacharya A; Derecki NC; Lovenberg TW; Drevets WC
    Psychopharmacology (Berl); 2016 May; 233(9):1623-36. PubMed ID: 26803500
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Adjunctive long-acting risperidone in patients with bipolar disorder who relapse frequently and have active mood symptoms.
    Macfadden W; Adler CM; Turkoz I; Haskins JT; Turner N; Alphs L
    BMC Psychiatry; 2011 Oct; 11():171. PubMed ID: 22034906
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Extent, Time Course, and Moderators of Antipsychotic Treatment in Youth With Mood Disorders: Results of a Meta-Analysis and Meta-Regression Analyses.
    Cervesi C; Park SY; Galling B; Molteni S; Masi G; Gerhard T; Olfson M; Correll CU
    J Clin Psychiatry; 2017 Mar; 78(3):347-357. PubMed ID: 28068462
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mechanisms of action and clinical efficacy of NMDA receptor modulators in mood disorders.
    Ghasemi M; Phillips C; Fahimi A; McNerney MW; Salehi A
    Neurosci Biobehav Rev; 2017 Sep; 80():555-572. PubMed ID: 28711661
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antipsychotics in the treatment of bipolar disorder.
    Singh J; Chen G; Canuso CM
    Handb Exp Pharmacol; 2012; (212):187-212. PubMed ID: 23129333
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Therapeutic potential of JAK/STAT pathway modulation in mood disorders.
    Shariq AS; Brietzke E; Rosenblat JD; Pan Z; Rong C; Ragguett RM; Park C; McIntyre RS
    Rev Neurosci; 2018 Dec; 30(1):1-7. PubMed ID: 29902157
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.